The Role of Triple CFTR Modulator Therapy in Reducing Systemic Inflammation in Cystic Fibrosis

Related articles

1. Small Airway Dysfunction and Type 2 Biomarkers Predict Exacerbations in Mild, Well-Controlled Asthma: A Retrospective Cohort Study

   This article has 5 authors:

   1. Guanhua Hou
   2. Zishuo Wang
   3. Yinan Xing
   4. Wei Li
   5. Limin Zhao

2. Organoid Guided N-of-1 (ORIGIN-1) Clinical Trial: A phase 4 study to investigate if people with cystic fibrosis with rare non-F508del CFTR mutations with an in-vitro response to Elexacaftor/ Tezacaftor/ Ivacaftor have a clinically meaningful response to Elexacaftor/ Tezacaftor/ Ivacaftor versus placebo.

   This article has 14 authors:

   1. Lorena Rodrigues Sabino
   2. Gerard E Kaiko
   3. Douglas Dorahy
   4. Thomas Thomas Goodsall
   5. Adam Jaffe
   6. Andre Schultz
   7. Shafagh Waters
   8. Dane Cook
   9. Harvey Kok
   10. Koliarne Tong
   11. James Totterdell
   12. James McGree
   13. Tom Snelling
   14. Peter AB Wark

3. Assessment of Pharmacotherapy and Clinical Outcomes of Treatment for the Development of Cardiovascular Disease among Tuberculosis Patients

   This article has 5 authors:

   1. Bheesham Kingrani
   2. Amer Hayat Khan
   3. Sabariah Noor Harun
   4. irfhan Ali Hyder Ali
   5. Azfar Athar Ishaqi